FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379339704> ?p ?o ?g. }

• W4379339704 endingPage "12052" @default.
• W4379339704 startingPage "12052" @default.
• W4379339704 abstract "12052 Background: Multiple myeloma is a disease of older adults with a median age at diagnosis of 68 years (y). Patients (pts) receiving chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory MM (RRMM) often experience detrimental effects due to frailty, comorbidity, and cumulative toxicities. In this study, we evaluated the prevalence and impact of frailty, defined by the simplified frailty score, (SFS; Facon et al, Leukemia 2020), and immuno-nutritional status, using Glasgow-prognostic score (GPS; Proctor et al, Br J Cancer 2011) in a real-world cohort of pts receiving CAR-T therapy for RRMM. Methods: We included all pts treated with commercial CAR-T therapy for RRMM between 2021 - 2023 at Moffitt Cancer Center. The SFS and GPS (CRP > 10 mg/dL, 1 point; albumin < 3.5, 1 point) were calculated for all pts at lymphodepletion. Primary endpoints included overall survival (OS) and progression free survival (PFS). Pearson’s chi-squared tests or Fisher’s exact tests were used to compare association between categorical variables. OS and PFS were estimated used using Kaplan-Meier methods; the log-rank test was used to compare OS and PFS, and a cox-proportional model was used for multivariable analysis (MVA). Results: A total of 139 pts were included, with a median follow up of 6.3 months (m; range, 0.2 to 20.3 m). Median age was 66 y (IQR, 58-72 y); 38% were ≥70 y. Pts were treated with either idecabtagene vicleucel (83%) or ciltacabtagene autoleucel (17%). Around 1/3 rd of pts had features of high-risk disease [high disease burden, 30%; high-risk cytogenetics (HR-Cyto), 37%; extramedullary disease (EMD), 37%]. Overall, 30% of pts were categorized as frail and 14% were classified as high-risk GPS (score = 2). There were no significant differences in GPS between older (≥70 y) and younger pts ( < 70 y; p= 0.8). Median OS in the cohort was not reached (NR) and median PFS was 11.7 m. Both frailty and high-risk GPS were associated with inferior PFS (frail vs non-frail, HR 2.0, p= 0.03, high GPS vs low/int, HR 1.7 p = 0.009) and OS (frail vs non-frail, HR 3.0, p = 0.006, high GPS vs low/intermediate, HR 2.1 p = < 0.001). The association of GPS with OS remained significant in a MVA, even after adjusting for high-risk disease factors (high disease burden, HR-Cyto and EMD) and frailty. Pts categorized as frail had a lower median PFS of 5.4 m (vs 12.7m non-frail group, p= 0.025), and inferior median OS of 9.7 m (vs NR in non-frail, p= 0.0039). Conclusions: In a real-world setting, frailty affects almost a third of pts with RRMM receiving CAR-T therapy and is associated with inferior PFS and OS. The GPS, a simple immuno-nutritional score, is highly predictive of survival even after adjusting for the presence of high-risk disease. Studies looking at role of pre-habilitation and other modalities to reduce inflammatory burden prior to CAR-T therapy are warranted." @default.
• W4379339704 created "2023-06-05" @default.
• W4379339704 creator A5001854462 @default.
• W4379339704 creator A5014453315 @default.
• W4379339704 creator A5018663825 @default.
• W4379339704 creator A5021394406 @default.
• W4379339704 creator A5035548614 @default.
• W4379339704 creator A5047518602 @default.
• W4379339704 creator A5047819225 @default.
• W4379339704 creator A5049496887 @default.
• W4379339704 creator A5053572690 @default.
• W4379339704 creator A5055261814 @default.
• W4379339704 creator A5062342454 @default.
• W4379339704 creator A5062691289 @default.
• W4379339704 creator A5064138486 @default.
• W4379339704 creator A5064716632 @default.
• W4379339704 creator A5077110117 @default.
• W4379339704 creator A5082565225 @default.
• W4379339704 creator A5087190330 @default.
• W4379339704 creator A5087799564 @default.
• W4379339704 date "2023-06-01" @default.
• W4379339704 modified "2023-09-27" @default.
• W4379339704 title "Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells." @default.
• W4379339704 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.12052" @default.
• W4379339704 hasPublicationYear "2023" @default.
• W4379339704 type Work @default.
• W4379339704 citedByCount "0" @default.
• W4379339704 crossrefType "journal-article" @default.
• W4379339704 hasAuthorship W4379339704A5001854462 @default.
• W4379339704 hasAuthorship W4379339704A5014453315 @default.
• W4379339704 hasAuthorship W4379339704A5018663825 @default.
• W4379339704 hasAuthorship W4379339704A5021394406 @default.
• W4379339704 hasAuthorship W4379339704A5035548614 @default.
• W4379339704 hasAuthorship W4379339704A5047518602 @default.
• W4379339704 hasAuthorship W4379339704A5047819225 @default.
• W4379339704 hasAuthorship W4379339704A5049496887 @default.
• W4379339704 hasAuthorship W4379339704A5053572690 @default.
• W4379339704 hasAuthorship W4379339704A5055261814 @default.
• W4379339704 hasAuthorship W4379339704A5062342454 @default.
• W4379339704 hasAuthorship W4379339704A5062691289 @default.
• W4379339704 hasAuthorship W4379339704A5064138486 @default.
• W4379339704 hasAuthorship W4379339704A5064716632 @default.
• W4379339704 hasAuthorship W4379339704A5077110117 @default.
• W4379339704 hasAuthorship W4379339704A5082565225 @default.
• W4379339704 hasAuthorship W4379339704A5087190330 @default.
• W4379339704 hasAuthorship W4379339704A5087799564 @default.
• W4379339704 hasConcept C121608353 @default.
• W4379339704 hasConcept C126322002 @default.
• W4379339704 hasConcept C143998085 @default.
• W4379339704 hasConcept C191093355 @default.
• W4379339704 hasConcept C2776364478 @default.
• W4379339704 hasConcept C50382708 @default.
• W4379339704 hasConcept C71924100 @default.
• W4379339704 hasConcept C72563966 @default.
• W4379339704 hasConcept C90924648 @default.
• W4379339704 hasConceptScore W4379339704C121608353 @default.
• W4379339704 hasConceptScore W4379339704C126322002 @default.
• W4379339704 hasConceptScore W4379339704C143998085 @default.
• W4379339704 hasConceptScore W4379339704C191093355 @default.
• W4379339704 hasConceptScore W4379339704C2776364478 @default.
• W4379339704 hasConceptScore W4379339704C50382708 @default.
• W4379339704 hasConceptScore W4379339704C71924100 @default.
• W4379339704 hasConceptScore W4379339704C72563966 @default.
• W4379339704 hasConceptScore W4379339704C90924648 @default.
• W4379339704 hasIssue "16_suppl" @default.
• W4379339704 hasLocation W43793397041 @default.
• W4379339704 hasOpenAccess W4379339704 @default.
• W4379339704 hasPrimaryLocation W43793397041 @default.
• W4379339704 hasRelatedWork W1411054225 @default.
• W4379339704 hasRelatedWork W2026086976 @default.
• W4379339704 hasRelatedWork W2596040508 @default.
• W4379339704 hasRelatedWork W2975501952 @default.
• W4379339704 hasRelatedWork W3104817578 @default.
• W4379339704 hasRelatedWork W3144899533 @default.
• W4379339704 hasRelatedWork W4304808194 @default.
• W4379339704 hasRelatedWork W4309244132 @default.
• W4379339704 hasRelatedWork W4311192294 @default.
• W4379339704 hasRelatedWork W4366351644 @default.
• W4379339704 hasVolume "41" @default.
• W4379339704 isParatext "false" @default.
• W4379339704 isRetracted "false" @default.
• W4379339704 workType "article" @default.